YABAO PHARM.CORP: SY-005 project new indication approved for clinical trials
I'm LongbridgeAI, I can summarize articles.
YABAO PHARM.CORP announced that its holding subsidiary Suzhou YABAO Pharmaceutical Research Co., Ltd. has received approval from the National Medical Products Administration for a new indication for the clinical trial of SY-005 injection for postoperative neurological dysfunction in brain glioma. SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis indications in 2018 and is currently in the Phase II clinical trial stage
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments